Yahoo
NasdaqCM - Delayed Quote USD

Longeveron Inc. (LGVN)

6.81 +0.23 (+3.50%)
At close: September 4 at 4:00:01 PM EDT
6.75 -0.06 (-0.88%)
After hours: September 4 at 7:30:02 PM EDT
Chart Range Bar
Loading chart for LGVN
  • Previous Close 6.58
  • Open 6.54
  • Bid 4.94 x 100
  • Ask 8.46 x 200
  • Day's Range 6.53 - 6.88
  • 52 Week Range 4.75 - 12.30
  • Volume 40,252
  • Avg. Volume 42,382
  • Market Cap (intraday) 21.712M
  • Beta (5Y Monthly) -0.26
  • PE Ratio (TTM) --
  • EPS (TTM) -10.00
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 71.50

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

longeveron.com

38

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LGVN
34.58%
S&P 500 (^GSPC)
12.75%

1-Year Return

LGVN
8.96%
S&P 500 (^GSPC)
18.71%

3-Year Return

LGVN
97.42%
S&P 500 (^GSPC)
70.93%

5-Year Return

LGVN
98.18%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 398k
Earnings -4.74M
Profit Margin -1,189.95%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-6M
-4M
-2M
0
-5000.0%
-4000.0%
-3000.0%
-2000.0%

Analyst Insights

View More

Analyst Price Targets

30.00
71.50 Average
6.81 Current
104.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/11/2026
Analyst Maxim Group
Rating Action Downgrade
Rating Hold
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -90.95%

  • Return on Equity (ttm)

    -203.61%

  • Revenue (ttm)

    1.19M

  • Net Income Avi to Common (ttm)

    -23.47M

  • Diluted EPS (ttm)

    -10.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.08M

  • Total Debt/Equity (mrq)

    5.58%

  • Levered Free Cash Flow (ttm)

    -11.6M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: